Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALPG | P10696 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15281239 | 0.87 | KMT2A (0.50) | PARP1LMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL18540704 | 0.83 | PARP1 (0.50) | PARP1LMNAL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL16214051 | 0.82 | MEN1 (0.46) | ALDH1A1MEN1KMT2ATDP1MLYCD | |
| SCHEMBL29852161 | 0.82 | PARP1 (0.57) | PARP1LMNAL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL1368532 | 0.82 | PARP1 (0.57) | PARP1LMNAL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL7077559 | 0.82 | MLYCD (0.44) | LMNAL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL4778395 | 0.82 | MLYCD (0.44) | LMNAL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL2652369 | 0.81 | HPGD (0.57) | PARP1MEN1KMT2ATDP1POLB | |
| SCHEMBL32424912 | 0.81 | HPGD (0.57) | PARP1MEN1KMT2ATDP1POLB | |
| SCHEMBL1515904 | 0.81 | CA12 (0.50) | PARP1ALDH1A1POLBMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190010173-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | MATEON THERAPEUTICS, INC. (US) | 2019-01-10 | — | — | US | claimed |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
| EP-4587126-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024057021-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-03-21 | — | — | WO | disclosed |
| EP-3368036-B1 | MACROCYCLIC PYRIDINE-N-OXIDE DERIVATIVES AS FACTOR XIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3218373-B1 | ANTI-HCMV COMPOSITIONS AND METHODS | EVRYS BIO LLC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190010173-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | MATEON THERAPEUTICS, INC. (US) | 2019-01-10 | — | — | US | disclosed |
| US-20180339977-A1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-11-29 | — | — | US | disclosed |
| EP-3368036-A1 | FACTOR XIA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017074832-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
| EP-0948257-A1 | TRIARYL SUBSTITUTED IMIDAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| US-5955480-A | GLUCAGON RECEPTOR ANTAGONISTS, CYTOKINE INHIBITORS | MERCK & CO., INC. (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0667855-B1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LAB (US) | 1999-03-24 | — | — | EP | disclosed |
| WO-1998021957-A1 | TRIARYL SUBSTITUTED IMIDAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| WO-1998022108-A1 | TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE | MERCK & CO., INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| US-5616596-A | Substituted arylalkynyl-and heteroarylalkynl-N-hydroxyurea inhibitors of leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1997-04-01 | — | — | US | disclosed |
| EP-0667855-A4 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS. | ABBOTT LAB (US) | 1996-02-21 | — | — | EP | disclosed |
| EP-0667855-A1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994011342-A1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1994-05-26 | — | — | WO | disclosed |
| US-5288751-A | [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | PARP1 3424/4885LMNA 1935/4885L3MBTL1 95/4885 |
| US-20190010173-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | CTSS, CTSB, CTSK | PARP1 1871/4885LMNA 2264/4885L3MBTL1 2604/4885 |
| US-20180339977-A1 | FACTOR XIA INHIBITORS | F11, SERPINC1, TFPI | PARP1 1381/4885LMNA 386/4885L3MBTL1 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.